Company intelligence / Profile preview

Convé

Oxford, Oxfordshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

Conve Therapeutics is a biotechnology company focused on developing transformative gene therapies for patients with neurodegenerative diseases. Spun out from the University of Oxford, the company's primary focus is on addressing GBA1-linked Parkinson's disease using advanced AAV-based delivery systems. Their approach aims to restore glucocerebrosidase activity in the brain to slow or halt disease progression. Conve is currently in the pre-clinical stage, advancing its lead candidate toward IND-enabling studies. The company is supported by Oxford Science Enterprises and leverages world-class expertise in CNS drug delivery and molecular biology.

Therapeutic areas: NeurologyRare Diseases
Modalities: Gene therapy
Industry: Biotech

Partnerships

University of Oxford

Beyond the preview

Go deeper on Convé.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Convé.

Explore the full profile